The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI, Inc. (TEM) entered into agreements with Bristol-Myers Squibb Company (BMS) and Pathos AI, Inc. to expand BMS’s access to oncology data and license neurology data and an analysis tool to Pathos for its collaboration with BMS. The agreements provide for aggregate cash payments to Tempus of $192.5 million over approximately five years: $137.5 million in fixed payments under the oncology statement of work and up to $55 million under the neurology order form.
The oncology work covers a license to de-identified multimodal records, access to Tempus’s Lens software and related services; its term ends December 31, 2031, with payments invoiced quarterly, and BMS may terminate on 12 months’ prior written notice and payment of a substantial termination fee. For neurology, Tempus will use commercially reasonable efforts to deliver and license 500,000 records of patients diagnosed with Alzheimer’s disease or other specified neurological conditions, at 100,000 per year for five years, and has granted Pathos a license to its Tempus Agent. Pathos’s fees are up to $55 million, including $50 million based on records delivered at $100 per record and $5.0 million for record updates. A special committee of disinterested Tempus directors approved the Neuro Order Form and Side Letter.
Tempus AI, Inc. (TEM) agreed to acquire Personalis through two mergers, subject to Personalis stockholder approval and other closing conditions. Personalis stockholders will vote on November 30, 2026; approval requires a majority of outstanding shares entitled to vote. If completed, Personalis would first become a wholly owned Tempus subsidiary, then the surviving entity would become Personalis, LLC, also wholly owned by Tempus.
For each eligible Personalis share, the exchange ratio is 0.3356 when Tempus’ defined stock price is at or below $48.42; above $48.42, it is $16.25 divided by that price. Tempus may elect cash consideration of $16.25 per share for up to 50% of outstanding Personalis shares, applied equally across holders and subject to automatic reduction to preserve the intended tax treatment. Tempus estimates issuing approximately 38,874,419 shares with a maximum 0.3356 exchange ratio and no cash election; under those assumptions, Personalis holders are expected to own up to approximately 18% of Tempus shares on a fully diluted basis. The HSR waiting period expired on October 2, 2026, and the CMA confirmed on August 13, 2026 that it had no further questions at that stage.
Tempus AI, Inc. (TEM) is registering Class A common stock for its proposed two-step merger with Personalis, Inc.; closing depends on Personalis stockholder approval and other conditions. Personalis would first become a Tempus subsidiary, then merge into Tempus subsidiary Toucan Development, LLC.
The stock component uses an exchange ratio of 0.3356 when Tempus Stock Price is $48.42 or less, and $16.25 divided by that price above $48.42. Before the third business day prior to closing, Tempus may elect $16.25 cash consideration per share for up to 50% of outstanding Personalis shares, applied equally across holders and subject to automatic reduction to preserve intended tax treatment. Tempus anticipates issuing a maximum of approximately 38,874,419 shares, assuming a 0.3356 exchange ratio and no cash election, based on Personalis shares outstanding and equity awards estimated as of October 15, 2026.
Personalis stockholders are scheduled to vote November 30, 2026; approval requires a majority of outstanding shares. The HSR waiting period expired October 2, 2026, and the CMA confirmed on August 13, 2026 that it had no further questions at that stage. Under the maximum-stock, no-cash scenario, Personalis holders are expected to own up to approximately 18% of Tempus Class A shares on a fully diluted basis.
Tempus AI, Inc. (TEM) has agreed to acquire Personalis, Inc. through two mergers, after which Personalis will be a wholly owned Tempus subsidiary. The transaction requires Personalis stockholder approval and other closing conditions; Tempus stockholders do not vote. Upon completion, each eligible Personalis share will convert into Tempus Class A common stock, with cash in lieu of fractional shares. At a Tempus Stock Price of $48.42 per share or less, the exchange ratio is 0.3356; above $48.42, it is $16.25 divided by the Tempus Stock Price.
Before the third business day before closing, Tempus may elect to pay $16.25 per Personalis share in cash for up to 50% of outstanding Personalis shares, applied equally across holders and subject to automatic reduction to preserve the Intended Tax Treatment. Personalis may terminate if the Tempus Stock Price is below $46.00 per share after final determination of the Exchange Ratio, but need not do so. Closing also requires the HSR waiting period to expire or terminate and CMA confirmation of no further questions, or clearance if it opens an investigation; the CMA said on August 13, 2026 that it had no further questions at that stage.
Tempus AI, Inc. (TEM) CEO, Diagnostics Thomas Edward Schoenherr sold 10,281 shares of Class A Common Stock at $85 per share on September 25, 2026, under a Rule 10b5-1 trading plan adopted March 3, 2026. He directly held 76,740 shares after the sale. The $85 figure is the reported per-share price.
Tempus AI, Inc. (TEM) officer Thomas Edward Schoenherr gave notice of a proposed sale of 10,281 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $845,509.44 and an approximate sale date of September 25, 2026. The shares were acquired upon vesting of restricted stock units from January 15 through February 15, 2026. During the prior three months, the notice lists sales of 2,694 shares for $188,580 on August 21, 2026, and 8,082 shares for $471,974.52 on August 19, 2026, each identified as 10b5-1 sales; it also lists a sale of 9,232 shares for $457,999.52 on August 18, 2026.
Tempus AI, Inc. (TEM) CEO and Chairman Eric P. Lefkofsky reported indirect sales by Gray Media, LLC, Blue Media, LLC, Lefkofsky Family Foundation and Vas.org Foundation totaling 250,000 Class A common shares on September 22, 2026. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted March 8, 2026; reported weighted-average sale prices were $76.57, $77.29, $78.23 and $78.86 per share.
As of September 22, 2026, the reported holdings included 2,098,130 shares directly and indirect holdings of 5,715,203 through Lefkofsky Family 2025 GRAT, 4,284,797 through Lefkofsky Family 2026 GRAT, 406 through 346 Long LLC and 206 through Black Media, LLC.
Tempus AI, Inc. (TEM) is the issuer for a Form 144 notice filed on behalf of Eric Lefkofsky covering proposed sales of Class A Common Stock. The filing lists up to 250,000 shares to be sold through J.P. Morgan Securities LLC, with an aggregate market value of $19,507,500 and reference to 175,390,967 shares outstanding as of September 22, 2026. The securities derive from stock compensation, direct investments, and a donation-related holding by Blue Media LLC. The notice also discloses recent sales over the prior three months by Blue Media LLC, Gray Media LLC, Lefkofsky Family Foundation, and Vas.org Foundation, entities for which Lefkofsky is the authorized signatory.
Tempus AI, Inc. reported that CEO and Chairman Eric P. Lefkofsky, a more than ten percent owner, reported the sale of 200,000 shares of Class A common stock on September 17, 2026 through affiliated entities at weighted average prices in ranges between $80.00–$80.92 and $81.00–$81.26, under a Rule 10b5-1 trading plan adopted on March 8, 2026. After these transactions, he holds shares both directly and through several LLCs, foundations, and grantor retained annuity trusts.